2026 Interim report
Filed with HKEX · Stock code 3933 · · 49 pages · English
2 Financial Highlights 3 Corporate Information 4 Report on Review of Condensed Consolidated Financial Statements 5 Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income 6 Condensed Consolidated Statement of Financial Position 8 Condensed Consolidated Statement of Changes in Equity 9 Condensed Consolidated Statement of Cash Flows 11 Notes to the Condensed Consolidated Fi
United Laboratories International Holdings Ltd. on 6ix
Earlier from United Laboratories International
- The group's product insulin degludec and liraglutide injection marketing registration application been accepted
- United Laboratories International Holdings: General mandates to issue securities and repurchase shares, re-election of directors and notice of annual general meeting
- Redemption notice
- United Laboratories International Holdings: U.S.$130,000,000 convertible bonds due 2021 adjustment to conversion price of the bonds
- Loan facility with china everbright bank - announcement pursuant to rule 13.18 of the listing rules
Later from United Laboratories International
- Notification Letter to Shareholder and Reply Form
- Notification Letter to Non-register Holder and Reply Form
- Second milestone payment from novo for exclusive license agreement of UBT251
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2026
Follow United Laboratories International into a list and get an email when it puts out news.
Follow United Laboratories International